Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.
Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.
MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.
Tumor location appears to be prognostic of PFS, OS, and predictive of response to biologic agents in KRAS wt mCRC.
Subanalysis of phase III RECOURSE trial suggests clinical benefit of TAS-102 in specific patients with metastatic CRC.
Survival benefit was consistent across prognostic criteria of grade, disease stage, lymph node involvement, and resection margins, and there was no significant difference in treatment-related serious adverse events between the 2 treatment arms.